Cindy Dubin
Cindy Dubin has been reporting on the pharmaceutical industry since 2003, with a particular focus on executive decision making regarding formulation, delivery, development, and commercialization. She is the former Editor-in-Chief of both Pharmaceutical Formulation & Quality and Specialty Pharma magazines. She is now a freelance writer.
-
![Arcturus_Payne_450x300]( "The Drug-Delivery Company That Partnerships Built")
The Drug-Delivery Company That Partnerships Built2/1/2019“Normally a company raises money, does their science, and hopes to get a deal. We were the inverse of that,” explains Joseph Payne, president and CEO of Arcturus Therapeutics.
-
![13_Iovance_1017_450x300]( "A Name Change — And More — For A Biotech")
A Name Change — And More — For A Biotech10/10/2017When Maria Fardis, Ph.D., MBA, joined Lion Biotechnologies as CEO, she knew “The word ‘Lion’ didn’t really define us as a company or the advancements we had made with our TIL technology.” So, nine months into her tenure, Fardis and her team began the process of changing the company name to Iovance.
